BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

NextEdge Admin

15 Nov 2024

2 min 36 sec

Microsoft Research,Providence Genomics,Journal of Clinical Oncology - Oncology Practice,CGP

A groundbreaking real-world study by Providence, Illumina (NASDAQ: ILMN), and Microsoft Research demonstrates that early Comprehensive Genomic Profiling (CGP) in cancer diagnosis significantly improves personalized treatment and patient outcomes. Published in *Journal of Clinical Oncology - Oncology Practice (JCO-OP)*, the first two years of this five-year study analyzed 3,216 advanced cancer patients.

The study used pathologist-driven CGP testing, delivering results 12 days before patients’ initial oncologist visits. This facilitated earlier, biomarker-informed decisions, with over half of the patients receiving targeted therapy or immunotherapy. Patients on targeted therapy achieved significantly longer survival (25 months) compared to those on chemotherapy alone (17 months, p<0.001).

Key findings include:
- CGP identified actionable mutations in 67% of tumors, compared to 33% with small-panel tests.
- 52% of CGP-tested patients received matched precision therapies, versus 32% receiving chemotherapy.

For non-small-cell lung cancer (NSCLC) patients, a related study revealed CGP's superior performance over small-panel tests, with higher actionable mutation rates (77% vs. 63%), greater use of matched therapies (64% vs. 50%), and improved survival (16 months vs. 7 months, p<0.0001).

Dr. Carlo Bifulco of Providence Genomics emphasized integrating CGP into standard care, as earlier biomarker-matched treatments significantly improve outcomes. CGP’s broad scope and faster results make it a vital tool in oncology, though barriers like insurance coverage persist.

Leveraging AI by Microsoft Research streamlined genomic interpretation and trial matching, expediting insights for molecular tumor boards. “This paradigm shift in oncology ensures better patient outcomes,” said Swaroop Aradhya of Illumina.

The findings advocate for widespread CGP adoption, highlighting its role in improving survival and driving precision oncology forward.